Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy
This study provides the first, concrete evidence that durvalumab rechallenge is effective for HCC patients who are refractory to anti-PD-1 therapy, especially for those who previously responded to anti-PD-1 treatment.
Authors
- Nai-Jung Chiang (ORCID: https://orcid.org/0000-0001-9292-0055)
- Yen‐Hao Chen (ORCID: https://orcid.org/0000-0002-5622-5490)
- San‐Chi Chen (ORCID: https://orcid.org/0000-0002-9436-5400)
- Kuan-Chang Lai
- Ming‐Huang Chen (ORCID: https://orcid.org/0000-0003-3187-7393)
- Yi-Ping Hung
Institutions
- National Yang Ming Chiao Tung University (TW)
- Chang Gung University (TW)
- Taipei Veterans General Hospital (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Hepatology International
- Published
- 2024-11-23
- DOI
- https://doi.org/10.1007/s12072-024-10728-9
- Citations
- 13
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.67
Funders
- Taiwan Clinical Oncology Research Foundation
- Taipei Veterans General Hospital